Claim/exemption information - Registry number 3494228

Case number
2022-068751
Claimant name
Stratasys Ltd.
Product identifier
Agilus yellow, FLX931
Claim type
Original
Date of filing
Non-compliance(s) identified on SDS and/or label
Yes, Order issued
SDS and/or label compliance review decision date
Claim/exemption status
Cancelled
Date of claim/exemption status

Additional information

Date of the order
Order status
Unresolved

List of suggested corrective measures

  • Disclose all headings as set out in column 1 of Schedule 1, specifically “Identification” and “Other information”.

  • Disclose an adequate product odour.

  • Disclose either the name of the symbol or the symbol itself for each of the applicable product hazard classifications, specifically “Skull and crossbones”.

  • Disclose the CAS registry number for “2-[[(butylamino)carbonyl]oxy]ethyl acrylate (main constituent >84%)”, “Exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acrylate”, and “oxybis(methyl-2,1-ethanediyl) diacrylate”.

  • Disclose the HMIRA registry number and correct date of decision granting the exemption, and clearly link which ingredients are part of the subject of the claim for exemption under the HMIRA. Additionally, remove the references to the HMIRA with respect to the subjects of the claim that are invalid.

  • Disclose the additional hazard classifications for the product (see appendix 1).

  • Disclose the appropriate hazard classification information for Skin Irritation - Category 2.

  • Disclose the common name and synonyms for the ingredients listed in section 3 of the SDS.

  • Disclose the correct and complete LD50 and LC50 values (see appendix 5).

  • Disclose the delayed and immediate effects, and chronic effects from short-term and long-term exposure.

  • Disclose the hazard statements for each of the product hazard classification categories or subcategories (see appendix 2).

  • Disclose the hazardous ingredients “2-[[(butylamino)carbonyl]oxy]ethyl acrylate (main constituent >84%)”, “Exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acrylate”, and “oxybis(methyl-2,1-ethanediyl) diacrylate”.

  • Disclose the most important effects, whether acute or delayed in section 4 of the SDS.

  • Disclose the percent of unknown acute oral toxicity and percent of unknown acute inhalation toxicity, and remove the misleading information regarding the percent of unknown acute toxicity.

  • Disclose the precautionary statements for each of the product hazard classification categories or subcategories (see appendix 2).

  • Disclose the product identifier "Agilus yellow, FLX931".

  • Disclose the product oral and inhalation (dust/mist) acute toxicity estimates (ATEs) of 1,600 mg/kg (33% unknown) and 0.29 mg/L (66% unknown), respectively, and remove the misleading information regarding the percent of unknown acute toxicity.

  • Disclose the relevant conditions for safe storage (see appendix 4).

  • Disclose the relevant first-aid measures (see appendix 3).

  • Disclose the relevant precautions for safe handling (see appendix 4).

  • Disclose the signal word “Danger”.

  • Disclose the telephone number of the initial Canadian supplier(s).

  • Remove all forward slashes or diagonal marks in precautionary statements for which a choice is to be made.

Date modified: